Work

Abstract PS2-07-03: Improved 3-year IDFS with anthracycline-based therapy for patients with 70-gene signature High 2, Luminal B, HR+HER2- early-stage breast cancer

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps2-07-03

Authors: J. O'Shaughnessy, A. Brufsky, C. L. Graham, C. R. Osborne, R. L. Rahman, A. Elkhanany, E. A. Brown, L. P. Gold, N. M. Johnson, D. Giffoni, J. Alberty-Oller, R. L. Mahtani, H. Ramaswamy, N. Stivers, A. Menicucci, W. Audeh

Institutions: Baylor University Medical Center, University of Pittsburgh, Texas Tech University, Texas Tech University Health Sciences Center, Baylor College of Medicine, Dan L Duncan Comprehensive Cancer Center, Legacy Health, London Health Sciences Centre, Kings County Hospital Center, Baptist Health South Florida, Agendia (United States)

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129654520

Cites:

Cited by:

Related to: